Trimethobenzamide An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM Levels and EffectsSummary of Use during LactationBecause no information is available on the continuous use of trimethobenzamide during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Occasional, short-term use of trimethobenzamide for the treatment of nausea and vomiting appears to be acceptable.[1]Drug LevelsMaternal Levels. Relevant published
Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Nausea and vomiting can occur in Parkinson's disease (PD) patients initiated on apomorphine subcutaneous injections and antiemetic prophylaxis is recommended per product labeling. Data suggest long-term antiemetic prophylaxis may not be needed, although this has not been systematically studied. We evaluated coadministered trimethobenzamide with apomorphine in 182 PD subjects using a randomized, double-blind, placebo-controlled design, with phased withdrawal of subjects from trimethobenzamide to placebo. Evaluations included presence/absence of nausea and vomiting; Index of Nausea, Vomiting, and Retching (INVR); subject
or Metoclopramide or metopimazine or nabilone or netupitant or norchlorpromazine or Olanzapine or Ondansetron or Palonosetron or pancopride or Prochlorperazine or Promazine or promethazine or ramosetron or renzapride or ricasetron or rolapitant or Scopolamine or sulpiride or telmapitant or tetrahydrocannabinol or Thiethylperazine or transmer or Trifluoperazine or Triflupromazine or trimethobenzamide
of oncology patients experiencing nausea from various chemotherapy regimens. Compared with placebo, trimethobenzamide, 200 mg IM every 6 hours for 2 days, significantly reduced episodes of N&V.[17]5-HT3 Receptor AntagonistsFour serotonin receptor antagonists—ondansetron, granisetron, dolasetron, and palonosetron—are available in the United States. Agents in this class are thought to prevent N&V
and vomiting during pregnancy. In cases refractory to standard therapy, ondansetron and steroids may be considered.The following medications may be used in women with hyperemesis gravidarum: * * Vitamins (eg, pyridoxine) * * Herbal medications (eg, ginger) * * Antiemetics (eg, doxylamine-pyridoxine, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, metoclopramide
up to two times a day over 3 days. Patients were pretreated with trimethobenzamide for 3 days, which was continued during the study. Of 19 patients, 15 (78.9%) achieved a full ON response. All 15 achieved a full ON response within 30 minutes and 6 of the 15 patients (40.0%) achieved a full ON response within 15 minutes. The mean (SD) duration of ON was 50 (19.4) minutes. Of the 15 patients, 9 (60.0
, and the full analysis set (FAS) included 88 patients. Patients completed a 7-day levodopa baseline period recording their time-to-ON following each morning dose of levodopa. Patients were titrated to an optimal dose of apomorphine (2-6 mg) while taking trimethobenzamide antiemetic therapy. Apomorphine was injected each morning for a 7-day treatment period and time-to-ON was self-recorded in 5-minute blocks